A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies.

Trial Profile

A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs TAK 733 (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 12 Sep 2016 Results published in the Investigational New Drugs
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 May 2013 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top